Clinical Trial Detail

NCT ID NCT02525692
Title Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Oncoceutics, Inc.
Indications

glioblastoma multiforme

malignant glioma

Therapies

ONC201

Age Groups: child adult senior

Additional content available in CKB BOOST